期刊文献+

抗HIV先导物DAAN-10341的体外代谢产物筛查

Metabolite Profiling of Anti-HIV Lead Compound DAAN-10341 in vitro
下载PDF
导出
摘要 目的应用超高效液相色谱-四极杆飞行时间质谱联用技术(UPLC-QTOF-MS/MS)并辅以代谢数据采集和处理软件,对新型非核苷类逆转录酶抑制剂(NNRTIs)的先导物DAAN-10341在大鼠肝微粒体的代谢产物进行快速筛查和鉴定,并对其结构中的代谢位点进行分析。方法应用质量亏损过滤技术在UPLC-QTOF-MS/MS上比较分析0 h与2 h孵育样品的数据,在大鼠肝微粒体孵育液中筛查得到了DAAN-10341的16个代谢产物。应用仪器的碰撞能量梯度功能(MSE)对部分产物进行MS2分析,获得代谢产物的碎片,推断碎裂途径及产物结构。结果先导物DAAN-10341在大鼠肝微粒体中的Ⅰ相代谢反应以氧化(羟基化)为主;Ⅱ相代谢主要以葡糖醛酸结合反应与谷胱甘肽结合反应为主。结论本文通过分析新型抗HIV先导物DAAN-10341的结构和代谢转化,发现易于发生代谢的位点和结构特征,为该类先导物结构优化和后续的临床前评价提供科学指导。 Objective The metabolite profiling of DAAN-10341, the lead compound from new classes of non-nucleoside reverse transcriptase inhibitors (NNRTIs) ,was performed using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS/MS), with the assistance of a metabolite data processing software. Methods Using the mass defect filter (MDF) technique, the data acquired from the 0 h-incubate and the 2 h-incubate were compared and analyzed with the software. A total of 16 metabolites were discovered for DAAN-10341 in the 2 h-incubate. The MS2 spectra for some metabolites were obtained using the MSE technique to get fragment ions for structural elucidation. Results Major metabolic pathways were identified. The compound could undergo extensive metabolism in rat liver rnicrosomes. The major phase Ⅰ reaction was oxidation/hydroxylation. The major reactions of phase Ⅱ were glucuronide conjugation and S-glutathione conjugation. Conclusion The structure-metabolic pathway relationship was analyzed to reveal metabolic soft spots and the structure characteristics of the compound, which may facilitate structural optimization of lead compounds,as well as preclinical evaluation of new chemical entities.
出处 《解放军药学学报》 CAS 2014年第2期93-99,共7页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 国家自然科学基金重点项目 No.30930106 国家"重大新药创制"科技重大专项 No.2008ZXJ09006-001
关键词 非核苷类逆转录酶抑制剂 二芳烃取代苯胺类化合物 大鼠肝微粒体 代谢产物 UPLC—QTOF—MS MS non-nucleoside reverse transcriptase inhibitors diarylaniline rat liver microsome metabolites UPLC-QTOF-MS/MS
  • 相关文献

参考文献16

  • 1刘涛,展鹏,刘新泳.二芳基胺类HIV-1非核苷类逆转录酶抑制剂研究进展[J].中国药物化学杂志,2013,23(1):55-62. 被引量:3
  • 2Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors [ J ]. Int J Biochem Cell Bio1,2004, 36(9) :1735 - 1751.
  • 3Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections [ J ]. Curt Opin Pharmacol,2004,4 ( 5 ) :437 - 446.
  • 4张兴权.抗艾滋病毒化学治疗药物的最新进展[J].药学学报,2010,45(2):194-204. 被引量:14
  • 5王柳,展鹏,刘新泳.结构优化策略在HIV非核苷类逆转录酶抑制剂设计中的应用[J].药学学报,2012,47(11):1409-1422. 被引量:6
  • 6Tian X, Qin B, Wu Z, et al. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors [ J ]. J Med Chem, 2010,53 ( 2 ) : 8287 - 8297.
  • 7Tian X, Qin B, Lu H, et al. Discovery of diarylpyridine derivatives as novel non-nueleoside HIV-I reverse transcriptase inhibitors [ J ]. Bioorg Med Chem Lett,2009,19 ( 18 ) :5482 - 5485.
  • 8Qin B, Jiang X, Lu H, et al. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors[ J]. J Med Chem,2010,53 ( 13 ) ,4906 - 4916.
  • 9Zhang DL, Zhu MS, Humphreys WG. Drug Metabolism in Drug De- sign and Development : Basic Concepts and Practice [ M ]. Beijing : People s Military Medical Press, 2011 : 167 ; 221 - 227.
  • 10王瑞,陈佳,秦炳杰,谢剑炜,李桦,谢蓝.两类抗HIV先导物的大鼠肝微粒体代谢产物筛查[J].药学学报,2012,47(12):1671-1677. 被引量:3

二级参考文献20

  • 1Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleo- side reverse transcriptase inhibitors[ J]. Ira J Biochem Cell Biol, 2004, 36(9) :1735-1751.
  • 2Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections [J]. C~rr Opin Pharmacol, 2004, 4(5) :437-446.
  • 3Tian X, Qin B, Wu Z, et al. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors[J]. J Med Chem, 2010, 53 : 8287 -8297.
  • 4Tian X, Qin B, Lu H, et al. Discovery of diarylpyridine deriva- tives as novel non-nucleoside HIV-1 reverse transcriptase inhibi- tors[J]. Bioorg Med Chem Lett, 2009, 19(18) :5482-5485.
  • 5Qin, B, Jiang X, Lu H, et al. Diarylaniline derivatives as a dis- tinct class of HIV-1 non-nucleoside reverse transcriptase inhibi- torsi J]. J Med Chem, 2010, 53 (13) :4906-4916.
  • 6Zhang DL, Zhu MS, Humphreys WG. Drug Metabolism in Drug Design and Development: Basic Concepts and Practice. [ M ] translated by Zhong DF, Li H,. Beijing: People's Military Medi- cal Press, 201l: 167, 221-227.
  • 7US Food and Drug Administration. Pharmacology review (s) of etravirine[ EB/OL]. (2008-01-15 ) [ 2013-07-03 ] http://www. aceessdata, fda. gov/drugsaffda _ docs/nda/2008/022187 s000 _ PharmR P1. pdf.
  • 8Yanakakis L.I, Bumpus NN. Biotransformation of the antiretrovi- ral drug etravirine: metabolite identifieation, reaction phenoty- ping, and eharacterization of autoinduction of eytochrome P450- dependent metabolism[ J ]. Drug Metab Dispos, 2012, 40 (4) : 803-814.
  • 9Ripamonti D, Maqqiolo F. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection[ J]. Curr Opin Investig D~gs, 2008, 9(8 ):899-912.
  • 10Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharma- cokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravifine and the in- tegrase inhibitor raltegravir in healthy subjects [ J ]. Antimicrob Agents Chemother, 2008, 52(12) :4228-4232.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部